Ytterligare ett abstract som visar värdet av AroCells provberedningssteg i samband med diagnostik har accepterats av ISOBM inför mötet i Hamburg
09 oct. 2018 02h40 HE
|
AroCell AB
AroCell meddelar idag att ytterligare ett abstract har accepterats av ISOBM (International Society of Oncology and BioMarkers) för presentation som poster vid organisationens årliga konferens i...
A second abstract accepted at ISOBM in Hamburg demonstrating enhanced diagnostic value when using AroCell’s proprietary sample preparation method
09 oct. 2018 02h40 HE
|
AroCell AB
AroCell AB announces today that a second abstract has been accepted by ISOBM (International Society of Oncology and BioMarkers) for poster presentation at the annual meeting in Hamburg, Germany...
Rhizen Pharmaceuticals S.A. announces preclinical data presentations for RP4010, a calcium release-activated calcium (CRAC) channel inhibitor and RP10107, a glutaminase inhibitor at the 2018 AACR Annual Meeting
10 avr. 2018 07h00 HE
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, April 10, 2018 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announces preclinical data presentations for RP4010, a novel first-in-class CRAC channel inhibitor and...
Rhizen Pharmaceuticals S.A. announces preclinical data presentations for RP4010, a novel first-in-class oral small molecule inhibitor of calcium release-activated calcium (CRAC) channel at 2017 AACR-NCI-EORTC International Conference, USA
24 oct. 2017 07h00 HE
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announces preclinical data presentations for RP4010, a novel first-in-class CRAC channel inhibitor in hematological...
Rhizen Pharmaceuticals S.A. to present Phase 1 clinical and additional preclinical data of RP6530 (dual PI3K delta/gamma inhibitor) in hematological malignancies
03 déc. 2014 07h00 HE
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, Dec. 3, 2014 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announces Phase 1 clinical and
additional preclinical data presentations for RP6530, a novel dual
PI3K...
Rhizen Pharmaceuticals S.A. announces preclinical presentations on RP6530, a dual PI3K delta/gamma inhibitor, for the treatment of hematological malignancies at the 55th Annual Meeting of the American Society of Hematology, 2013
19 nov. 2013 06h35 HE
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, Nov. 19, 2013 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announces poster presentations for
its clinical lead, RP6530, a novel, dual Phosphoinositide-3...